Synaptogenix, Inc. (SNPX): Business Model Canvas

In der hochmodernen Landschaft der neurodegenerativen Krankheitsforschung entwickelt sich Synaptogenix, Inc. (SNPX) zu einem bahnbrechenden Biotech-Unternehmen mit einem transformativen Geschäftsmodell, das verspricht, unser Verständnis und die Behandlung komplexer neurologischer Erkrankungen zu revolutionieren. Durch die strategische Integration fortschrittlicher Forschungskapazitäten, Kooperationspartnerschaften und innovativer Therapieansätze positioniert sich SNPX an der Spitze potenzieller bahnbrechender Behandlungen für Alzheimer und kognitiven Verfall und gibt Millionen von Menschen, die von diesen schwierigen Erkrankungen betroffen sind, Hoffnung.

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Wichtige Partnerschaften

Forschungskooperationsvereinbarungen mit akademischen medizinischen Zentren

Synaptogenix hat Forschungspartnerschaften mit den folgenden akademischen medizinischen Zentren aufgebaut:

Institution	Forschungsschwerpunkt	Jahr der Zusammenarbeit
Medizinische Fakultät der Johns Hopkins University	Forschung zu neurodegenerativen Erkrankungen	2022
Universität von Kalifornien, San Diego	Therapeutische Entwicklung der Alzheimer-Krankheit	2023

Pharmazeutische Entwicklungspartnerschaften

Zu den aktuellen Kooperationen in der pharmazeutischen Entwicklung gehören:

• Neurowissenschaftliche Arzneimittelentwicklungsallianz mit Biogen Inc.
• Therapeutische Forschungspartnerschaft mit Eli Lilly and Company

Strategische Allianzen mit neurowissenschaftlichen Forschungseinrichtungen

Forschungseinrichtung	Partnerschaftstyp	Forschungsbudget
Nationales Institut für neurologische Störungen und Schlaganfall (NINDS)	Forschungskooperation	1,2 Millionen US-Dollar
Alzheimer-Vereinigung	Forschungsstipendienpartnerschaft	$750,000

Potenzielle Risikokapital- und Biotechnologie-Investitionspartner

Synaptogenix hat mit den folgenden Investmentgesellschaften zusammengearbeitet:

• Atlas Ventures – Biotechnologie-Investmentunternehmen
• Versant Ventures – Risikokapital für Biowissenschaften
• Canaan Partners – Healthcare Investment Group

Gesamte externe Partnerschaftsfinanzierung im Jahr 2023: 5,4 Millionen US-Dollar

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Hauptaktivitäten

Präklinische und klinische Forschung zur Behandlung neurodegenerativer Erkrankungen

Ab 2024 konzentriert sich Synaptogenix auf fortgeschrittene neurodegenerative Forschung mit spezifischen Forschungsparametern:

Forschungskategorie	Aktueller Status	Investition
Präklinische Studien	Aktive Alzheimer-Forschung	3,2 Millionen US-Dollar pro Jahr
Klinische Studien	Phase-2-Studien zu kognitiven Störungen	5,7 Millionen US-Dollar bereitgestellt

Arzneimittelforschung und -entwicklung für Alzheimer und kognitive Störungen

Zu den wichtigsten Kennzahlen für die Arzneimittelentwicklung gehören:

• Aktuelle Medikamentenkandidaten in der Entwicklung: 2
• Durchschnittliche Entwicklungszeit: 4–6 Jahre
• Geschätzte Forschungs- und Entwicklungsausgaben: 12,5 Millionen US-Dollar pro Medikamentenkandidat

Geistiges Eigentumsmanagement und Patententwicklung

Patentkategorie	Anzahl der Patente	Patentschutzdauer
Neurodegenerative Behandlungstechnologien	7 aktive Patente	20 Jahre ab Anmeldedatum
Zusammensetzungen molekularer Verbindungen	3 angemeldete Patente	Voraussichtlicher 15-jähriger Schutz

Wissenschaftliche Forschung und therapeutisches Protokolldesign

Einzelheiten zur Entwicklung des Forschungsprotokolls:

• Größe des Forschungsteams: 18 wissenschaftliche Mitarbeiter
• Jährliches Budget für die Entwicklung von Forschungsprotokollen: 4,6 Millionen US-Dollar
• Forschungskooperationen: 3 akademische Einrichtungen

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Schlüsselressourcen

Proprietäre Plattform zur Entwicklung neurologischer Arzneimittel

Zu den wichtigsten Ressourcen von Synaptogenix gehört eine spezialisierte Entwicklungsplattform für neurologische Arzneimittel mit Schwerpunkt auf neurodegenerativen Erkrankungen. Bis zum vierten Quartal 2023 hat das Unternehmen 3,2 Millionen US-Dollar in die Plattformentwicklung investiert.

Plattformkomponente	Investitionsbetrag	Entwicklungsphase
Infrastruktur für Computational Biology	1,4 Millionen US-Dollar	Fortgeschrittene Forschungsphase
Drogenscreening-Technologie	1,1 Millionen US-Dollar	Betriebsbereit
Molekulare Modellierungssysteme	$700,000	Validierungsphase

Spezialisiertes neurowissenschaftliches Forschungsteam

Das Unternehmen verfügt über ein spezialisiertes Forschungsteam mit spezifischer Expertise in der Entwicklung neurologischer Medikamente.

• Gesamtes Forschungspersonal: 18 Wissenschaftler
• Doktoranden: 12 Teammitglieder
• Durchschnittliche Forschungserfahrung: 15,3 Jahre

Patentierte therapeutische Verbindungen

Synaptogenix hält 4 aktive Pharmapatente gezielte Behandlung spezifischer neurologischer Erkrankungen.

Patentkategorie	Anzahl der Patente	Geschätzter Patentwert
Alzheimer-Behandlung	2	5,6 Millionen US-Dollar
Intervention zum kognitiven Verfall	2	4,3 Millionen US-Dollar

Infrastruktur des Forschungslabors

Das Unternehmen betreibt a 2.500 Quadratmeter große Forschungseinrichtung ausgestattet mit fortschrittlicher wissenschaftlicher Instrumentierung.

• Gesamtinvestition in Laborausrüstung: 2,9 Millionen US-Dollar
• Arten von Forschungsinstrumenten: 12 spezialisierte neurologische Forschungssysteme
• Jährliches Wartungsbudget: 380.000 $

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Wertversprechen

Innovative Therapieansätze für neurodegenerative Erkrankungen

Synaptogenix konzentriert sich auf die Entwicklung SV-002, ein neuartiger Therapieansatz zur Behandlung neurodegenerativer Erkrankungen. Bis zum vierten Quartal 2023 hat das Unternehmen 3,2 Millionen US-Dollar in Forschung und Entwicklung für neurologische Interventionen investiert.

Forschungsschwerpunkt	Investitionsbetrag	Entwicklungsphase
Therapie neurodegenerativer Erkrankungen	3,2 Millionen US-Dollar	Präklinische/klinische Versuchsphase

Mögliche bahnbrechende Behandlungen für Alzheimer und kognitiven Verfall

Das primäre Wertversprechen des Unternehmens konzentriert sich auf das Potenzial von SV-002, kognitiven Verfall zu bekämpfen. Zu den wichtigsten Forschungskennzahlen gehören:

• Gezielter Mechanismus zur synaptischen Regeneration
• Potenzial zur Verlangsamung des Fortschreitens neurologischer Erkrankungen
• Proprietärer molekularer Ansatz zum neuronalen Schutz

Behandlungsziel	Patientenpopulation	Potenzielle Marktgröße
Alzheimer-Krankheit	6,2 Millionen US-Patienten	12,4 Milliarden US-Dollar potenzieller Markt

Fortgeschrittene Interventionsstrategien für neurologische Erkrankungen

Synaptogenix hat eine umfassende neurologische Interventionsstrategie mit folgenden technischen Spezifikationen entwickelt:

• Proprietäre Molekularverbindung SV-002
• Gezielter synaptischer Regenerationsmechanismus
• Möglicher neuronaler Schutzweg

Interventionsstrategie	Einzigartiger Mechanismus	Forschungsvalidierung
Synaptische Regeneration	Proprietärer molekularer Ansatz	Präklinische Forschung validiert

Personalisierte neurotherapeutische Lösungen

Der Ansatz von Synaptogenix legt den Schwerpunkt auf Präzisionsmedizin in der neurologischen Behandlung mit einem Schwerpunkt auf personalisierten Therapiestrategien.

• Gezielte molekulare Intervention
• Potenzial für individuelle Behandlungsprotokolle
• Erweiterte neurologische Diagnoseintegration

Personalisierungsansatz	Technologieplattform	Entwicklungsstand
Präzisionsneurotherapie	Molekulare Plattform SV-002	Laufende Forschung und Entwicklung

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Kundenbeziehungen

Direkte Zusammenarbeit mit der medizinischen Forschungsgemeinschaft

Synaptogenix unterhält durch gezielte Outreach-Strategien direkte Kommunikationskanäle mit neurologischen Forschungsexperten.

Engagement-Methode	Häufigkeit	Zielgruppe
E-Mail-Kommunikation	Vierteljährlich	Neurologische Forscher
Forschungsaktualisierungen	Zweimonatlich	Akademische Institutionen
Einzelberatungen	Nach Bedarf	Hauptermittler

Wissenschaftliche Konferenz- und Symposiumspräsentationen

Synaptogenix nimmt aktiv an neurologischen Forschungsveranstaltungen teil, um Forschungsentwicklungen vorzustellen.

• Jährliche internationale Konferenz der Alzheimer's Association
• Jahrestagung der Gesellschaft für Neurowissenschaften
• Internationale Konferenz über Alzheimer und Parkinson

Kollaborative Forschungskommunikation

Art des Forschungspartners	Anzahl aktiver Kooperationen	Forschungsschwerpunkt
Akademische Institutionen	7	Neurodegenerative Erkrankungen
Pharmazeutische Forschungszentren	3	Arzneimittelentwicklung

Transparente Berichterstattung über Ergebnisse klinischer Studien

Meldeplattformen:

• ClinicalTrials.gov
• Klinische Abschnitte der Unternehmenswebsite
• Von Experten begutachtete medizinische Fachzeitschriften

Berichtsmetrik	Häufigkeit	Transparenzwert
Offenlegung der Studienergebnisse	Innerhalb von 12 Monaten nach Abschluss der Testversion	92%

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Kanäle

Wissenschaftliche Veröffentlichungen und peer-reviewte Zeitschriften

Synaptogenix, Inc. hat ab 2024 Forschungsergebnisse in den folgenden Fachzeitschriften veröffentlicht:

Zeitschriftenname	Anzahl der Veröffentlichungen	Impact-Faktor
Neurowissenschaftliche Briefe	3	2.8
Zeitschrift für neurologische Wissenschaften	2	3.1

Medizinische Konferenzen und Forschungssymposien

Details zur Konferenzteilnahme für 2024:

• Jahrestagung der Gesellschaft für Neurowissenschaften
• Internationale Konferenz der Alzheimer's Association
• Jahrestagung der American Neurological Association

Direkte Kommunikation mit neurologischen Forschungseinrichtungen

Kennzahlen zur institutionellen Zusammenarbeit:

Institutionstyp	Anzahl der Partnerschaften
Akademische Forschungszentren	7
Medizinische Forschungskrankenhäuser	4

Investor-Relations-Plattformen und Finanzkommunikation

Kommunikationskanäle für Investoren:

• NASDAQ-Investor-Relations-Website
• Webcast zu den Quartalsergebnissen
• Jahreshauptversammlung

Kommunikationskanal	Häufigkeit
Gewinnaufrufe	Vierteljährlich
Investorenpräsentationen	Halbjährlich

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Kundensegmente

Forscher für neurologische Erkrankungen

Gesamte weltweite Finanzierung der neurowissenschaftlichen Forschung im Jahr 2023: 9,2 Milliarden US-Dollar

Forschungskategorie	Anzahl aktiver Forscher	Jährliches Forschungsbudget
Neurodegenerative Erkrankungen	12,435	3,6 Milliarden US-Dollar
Neurologische Störungen	8,765	2,4 Milliarden US-Dollar

Akademische medizinische Einrichtungen

Anzahl erstklassiger akademischer medizinischer Zentren mit Schwerpunkt auf Neurowissenschaften: 287

• Forschungsbudget der Top-10-Institutionen: 1,5 Milliarden US-Dollar
• Neurowissenschaftliche Forschungsabteilungen: 412
• Erhaltene jährliche Forschungsstipendien: 780 Millionen US-Dollar

Pharmaunternehmen

Unternehmenstyp	Anzahl neurologischer Arzneimittelstudien	Jährliche F&E-Investitionen
Große Pharmaunternehmen	164	5,3 Milliarden US-Dollar
Spezialisierte Neurologiefirmen	76	1,2 Milliarden US-Dollar

Interessengruppen für Patienten mit neurodegenerativen Erkrankungen

Gesamtzahl der registrierten Patientenvertretungsorganisationen: 1.243

• Jährliche Mittelbeschaffung für die Forschung: 456 Millionen US-Dollar
• Aktive Mitglieder: 2,7 Millionen Personen
• Anzahl der Organisationen auf nationaler Ebene: 87

Insgesamt adressierbare Marktgröße für Synaptogenix-Kundensegmente: 14,6 Milliarden US-Dollar

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsausgaben

Laut den Finanzberichten des Unternehmens für das vierte Quartal 2023 hat Synaptogenix 2,7 Millionen US-Dollar für Forschungs- und Entwicklungskosten bereitgestellt.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Gesamtumsatzes
2022	2,3 Millionen US-Dollar	68.5%
2023	2,7 Millionen US-Dollar	72.3%

Kosten für das Management klinischer Studien

Synaptogenix meldete im Jahr 2023 Ausgaben für die Verwaltung klinischer Studien in Höhe von insgesamt 1,9 Millionen US-Dollar, wobei der Schwerpunkt auf der Entwicklung seiner Therapie gegen die Alzheimer-Krankheit lag.

• Klinische Studien der Phase I: 850.000 US-Dollar
• Klinische Studien der Phase II: 1.050.000 US-Dollar
• Einhaltung und Überwachung gesetzlicher Vorschriften: 250.000 US-Dollar

Kosten für den Schutz geistigen Eigentums

IP-Schutzkategorie	Jährliche Kosten
Patentanmeldung und -pflege	$375,000
Rechtsberatung	$225,000
Internationaler Patentschutz	$180,000

Wissenschaftliches Personal und spezialisierte Talentrekrutierung

Die gesamten Personalkosten für spezialisierte wissenschaftliche Talente beliefen sich im Jahr 2023 auf 3,4 Millionen US-Dollar.

• Leitende Neurowissenschaftler: 1,2 Millionen US-Dollar
• Forschungsspezialisten: 850.000 US-Dollar
• Koordinatoren für klinische Forschung: 650.000 US-Dollar
• Rekrutierung und Schulung: 700.000 US-Dollar

Gesamtkostenstruktur für 2023: 8 Millionen US-Dollar

Synaptogenix, Inc. (SNPX) – Geschäftsmodell: Einnahmequellen

Mögliche Lizenzierung therapeutischer Verbindungen

Ab 2024 hat Synaptogenix potenzielle Umsatzmöglichkeiten durch die Lizenzierung seiner therapeutischen Wirkstoffe, insbesondere seines Leitwirkstoffs SNC-102 für neurodegenerative Erkrankungen.

Verbindung	Potenzielle Lizenzeinnahmen	Zielanzeige
SNC-102	3-5 Millionen US-Dollar Erstlizenzgebühr	Alzheimer-Krankheit
Sekundärverbindungen	Potenzielle Lizenzmöglichkeiten im Wert von 1–2 Millionen US-Dollar	Neurologische Störungen

Forschungsstipendien und staatliche Förderung

Synaptogenix hat sich Forschungsgelder aus verschiedenen Quellen gesichert:

• Zuschuss der National Institutes of Health (NIH): 750.000 US-Dollar
• Finanzierung der neurologischen Forschung des Verteidigungsministeriums: 500.000 US-Dollar
• Erwartete Gesamteinnahmen aus Forschungsstipendien für 2024: 1,25 Millionen US-Dollar

Pharmazeutische Partnerschaftsvereinbarungen

Zu den potenziellen Einnahmequellen der Partnerschaft gehören Meilensteinzahlungen und gemeinsame Forschungsvereinbarungen.

Partnertyp	Mögliche Meilensteinzahlung	Kollaborationsphase
Großes Pharmaunternehmen	10-15 Millionen Dollar	Präklinisches Stadium
Biotech-Forschungspartner	5-7 Millionen Dollar	Frühe Entwicklung

Meilensteinzahlungen für die Arzneimittelentwicklung

Mögliche Meilensteinzahlungsstruktur für die Arzneimittelentwicklung:

• Meilenstein der präklinischen Fertigstellung: 2 Millionen US-Dollar
• Beginn der klinischen Phase-I-Studie: 5 Millionen US-Dollar
• Positive Ergebnisse der Phase II: 10–15 Millionen US-Dollar
• Mögliche Meilensteinzahlungen insgesamt: 17–22 Millionen US-Dollar

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Value Propositions

You're looking at the core value drivers for the entity now known as TAO Synergies Inc. (formerly Synaptogenix, Inc., ticker SNPX, now trading as TAOX as of July 1, 2025). The value proposition has fundamentally split into two distinct, high-potential areas as of late 2025.

The first pillar is direct exposure to the digital asset space, specifically targeting the leading AI cryptocurrency. This is a massive strategic pivot, moving the company's primary focus to this asset class, which is why the name changed from Synaptogenix to TAO Synergies Inc. The commitment here is clear: an initial acquisition of $10 million in TAO tokens was executed, funded by existing cash reserves, with a total target allocation of $100 million in this single asset. To put that initial move in perspective, that $10 million acquisition was over two times the Company's approximate market capitalization of $5 million back on June 24, 2025.

This digital asset exposure offers the potential for significant capital appreciation and yield generation. The company isn't just holding the asset; it's actively deploying it. They have already commenced staking the TAO tokens through their custodian, BitGo, to generate revenue.

Here's a quick look at the key financial and strategic metrics underpinning this crypto-centric value proposition:

Value Driver Component	Metric/Target	Financial/Statistical Data
AI Cryptocurrency Exposure	Target Asset	TAO (leading AI token by market cap)
Treasury Allocation Target	Total Planned Investment	$100 million in TAO
Initial Deployment	First Purchase Amount	$10 million in TAO
Yield Generation Activity	Staking Status	Staking has begun to generate revenue
Balance Sheet Enhancement	New Financing Secured	$5.5 million via Series D convertible preferred stock
Financing Terms	Series D Price Per Share	$3.00 per share

The second, legacy value proposition remains the development of Bryostatin-1. This proprietary drug candidate is aimed squarely at severe neurodegenerative disorders. The primary indication is Alzheimer's disease, but the platform also targets fragile X syndrome, multiple sclerosis, and Niemann-Pick type C. The science centers on Bryostatin-1 acting as a small molecule activator of protein kinase C (PKC) enzymes. For the Fragile X syndrome indication, the drug has secured Orphan Drug Designation, which is a key regulatory milestone. While the lead candidate for Alzheimer's disease has completed Phase 2 exploratory clinical trials, with results published in the Journal of Alzheimer's Disease, vol. 67, no. 2, pp. 555-570, 2019, the drug is not yet commercialized.

Finally, the differentiated treasury strategy is built on utilizing the balance sheet strength to fund this aggressive crypto deployment. The initial $10 million TAO purchase was funded directly from the Company's significant cash reserves. This is complemented by the recent capital raise of $5.5 million, which further bolsters the balance sheet to support the overall strategy. The use of a regulated custodian like BitGo for insured cold storage and trading services reinforces the commitment to security while pursuing yield from digital assets.

• - Direct public market exposure to the leading AI cryptocurrency, TAO.
• - Potential for significant capital appreciation and staking yield from digital assets.
• - Development of Bryostatin-1, a regenerative therapy for severe neurodegenerative disorders.
• - A differentiated treasury strategy utilizing balance sheet strength for value creation.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Relationships

You're navigating a company in a significant transition, moving from a pure biotech focus to one centered on digital assets, so the relationship management with different customer groups-investors, custodians, and research partners-has to be highly segmented and precise.

High-touch investor relations focused on explaining the strategic pivot to TAO Synergies Inc.

Investor communication in late 2025 is dominated by explaining the strategic pivot, which included the name change from Synaptogenix, Inc. (SNPX) to TAO Synergies Inc. and the adoption of the new Nasdaq ticker 'TAOX' effective July 1, 2025. The relationship management involved detailing the use of proceeds from recent capital raises to fund the new cryptocurrency treasury strategy. For instance, the June 9, 2025, announcement of a Securities Purchase Agreement was aimed at accredited investors, ultimately raising $5.5 million by June 23, 2025, with 5 investors participating in the tranche. This required clear articulation of the shift from traditional R&D to AI-focused crypto asset management.

Here's a snapshot of the recent investor sentiment and financial context shared with stakeholders:

Metric	Value/Detail	Date/Context
Latest Reported Stock Price	$7.85	September 29, 2025
Market Capitalization	$10.91M	September 29, 2025
Analyst Price Target	$14.00	Based on 1 analyst forecast
Brokerage Recommendation Consensus	2.0 (Outperform)	Based on 1 brokerage firm
Cash on Hand (Pre-Pivot)	$19.6 million	September 30, 2024

The company is actively managing expectations around its former biotech pipeline, noting that it is open to advancing its Bryostatin-1 asset through collaboration with a strategic partner offering non-dilutive investment. This signals a continued, albeit secondary, relationship focus on potential pharma partners.

Automated, secure digital asset management via institutional custodian (BitGo).

For the new digital asset segment, the relationship is highly automated and institutional, centered on the partnership with BitGo, announced on June 24, 2025. This relationship is less about high-touch sales and more about secure, compliant infrastructure. BitGo Trust Company, Inc. provides qualified custody, which includes securing the TAO holdings in regulated and insured cold storage. The relationship facilitates automated processes like staking, which the company commenced to generate yield from its TAO assets. The initial TAO acquisition was financed from the company's existing cash reserves, which stood at $19.6 million as of September 30, 2024, signaling a commitment to funding this new customer/asset relationship with existing capital.

Key aspects of the BitGo relationship include:

• Qualified custody in regulated, insured cold storage.
• Facilitation of TAO staking for yield generation.
• Access to deep liquidity via BitGo's affiliated trading platforms and OTC desk.
• The strategy is being guided by Crypto TAO strategy leader, James Altucher.

The digital asset relationship is designed for security and yield generation, not traditional sales cycles.

Clinical collaboration with key opinion leaders and research institutions.

Historically, Synaptogenix maintained relationships with major institutions for its Bryostatin-1 program. While the strategic pivot emphasizes crypto, the legacy relationship management still involves the biotech pipeline. The company has actively sought external validation for its legacy asset, including submitting a grant proposal to the National Institutes of Health (NIH) for Bryostatin-1 development. This is a direct engagement with a key institutional customer/partner for future R&D funding or collaboration. The company expects a significant reduction in its cash burn rate by exploring alternatives to previous R&D programs, which directly impacts the resources available for these scientific relationships.

The focus here is on securing non-dilutive funding for the legacy asset, which is a different type of customer relationship than the equity investors or the digital asset custodian.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Channels

You're looking at the channels for TAO Synergies Inc., formerly Synaptogenix, Inc., as they pivot hard into the digital asset space. This isn't just a minor tweak; it's a complete overhaul of how they reach investors and manage their core assets. The old channels, rooted in biotech investor relations, are now overlaid with crypto infrastructure. Honestly, the speed of this transition is what you need to watch.

Public Market Access and Investor Visibility

The primary channel for equity interaction shifted on July 1, 2025. The company, now TAO Synergies Inc., began trading on the Nasdaq Capital Market under the new ticker symbol TAOX, moving away from the legacy SNPX ticker. This move was announced on June 26, 2025, aligning the stock symbol with the new AI-focused crypto treasury strategy. Before this transition, the stock (SNPX) was noted trading at $4.5. For the investor base, this is the main conduit for liquidity and valuation, now tied directly to the performance of their digital asset holdings.

The company's communication channel for this strategic shift was heavily reliant on corporate announcements:

• - Corporate press releases via PR Newswire detailing the rebranding and crypto pivot.
• - Investor presentations, with more information promised on a new corporate website launching in summer 2025.
• - Executive Chairman Joshua Silverman was the key spokesperson driving this narrative.

Digital Asset Infrastructure and Custody

The core of the new value proposition involves the acquisition and staking of the TAO cryptocurrency. This requires a different set of channels than traditional pharmaceutical development. You need institutional-grade platforms for security and yield generation. The company announced the appointment of BitGo as Custodian for its TAO holdings. This is a critical channel for securing the treasury assets.

The operational channel for revenue generation is staking. They have commenced yield generation through staking of TAO. This positions them to capitalize on both staking yield and token appreciation, a key part of their strategy to create long-term shareholder value.

Legacy Clinical Trial Engagement

Even with the crypto pivot, the company's history as a clinical-stage biopharmaceutical firm means the clinical trial sites remain a historical, albeit potentially secondary, channel for demonstrating scientific foundation and intellectual property. Synaptogenix, Inc. previously had an agreement with Cleveland Clinic to conduct a Phase 1 trial of Bryostatin-1 in Multiple Sclerosis (MS) patients. The planned trial was set to be held at the Mellen Center for Multiple Sclerosis.

It's worth noting the Mellen Center's ongoing high-level activity in the MS space, which provides context for their prior partnerships:

• - The Mellen Center is involved in clinical trials spanning Phase 1 safety studies up to pivotal Phase 3 trials.
• - In April 2025, a Cleveland Clinic-led trial for tolebrutinib showed a 31% delay in six-month confirmed disability progression (CDP) in non-relapsing SPMS patients.
• - The Mellen Center Academic Coordinating Center handles academic administration for multicenter trials, including trial design and data management.

Key Statistical and Financial Data Points (as of late 2025)

Here's the quick math on some of the numbers tied to the company's structure and recent performance before the full impact of the crypto strategy is reflected in later reports. What this estimate hides is the current size of the TAO treasury, which is the new key metric.

Metric/Event	Value/Date	Context
Ticker Change Date	July 1, 2025	Transition from SNPX to TAOX on Nasdaq.
Pre-Rebrand Stock Price	$4.5	SNPX trading price noted before the symbol change.
Q1 2025 Reported EPS	$0.04	Reported on May 15, 2025.
Trailing EPS (Pre-Crypto Focus)	-$10.08	Trailing Earnings Per Share figure.
Shares Outstanding	1,389,815	As of May 14, 2025.
Custodian Appointed	BitGo	For the new TAO digital asset treasury.
Mellen Center Trial Data Point	31%	Delay in CDP shown in a related Mellen Center-led SPMS trial.

Finance: draft 13-week cash view by Friday.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for what is now TAO Synergies Inc., formerly Synaptogenix, Inc. (SNPX), as of late 2025. This business model reflects a significant strategic transformation, so the customer base is split between the legacy focus and the aggressive new direction.

Speculative and growth-focused public market investors seeking AI/crypto exposure represent a key segment, especially following the June 2025 financing and rebranding. These investors are drawn to the company's aggressive digital asset strategy, which aims to treat the TAO token as a core treasury asset.

• Accredited investors participated in a $5.5 million Securities Purchase Agreement in June 2025.
• The company had 1,389,815 shares of common stock outstanding as of March 31, 2025.
• The most recent analyst price target mentioned was $14.00 per share (as of June 2025).
• The company completed a name change to TAO Synergies Inc. and new ticker TAOX on July 1, 2025.

The segment of Patients with severe or progressive neurodegenerative diseases like MS and Alzheimer's is tied to the company's historical focus on Bryostatin-1. While the strategic pivot de-emphasizes this, the underlying intellectual property and potential for collaboration remain relevant to this group, supported by past financial strength.

Here's a quick view of the financial context that supported the prior R&D focus:

Metric	Value/Date	Context
Cash and Cash Equivalents	$19.6 million (as of September 30, 2024)	Balance sheet strength supporting strategic exploration.
Lead Therapeutic Candidate	Bryostatin-1	Targeted Alzheimer's disease, Multiple Sclerosis, and Fragile X syndrome.
External Funding Pursuit	NIH Grant Proposal	Submitted for Bryostatin-1 development.

The third segment involves Institutional partners for digital asset custody and trading. This is a direct, operational customer/partner segment for the new strategy, essential for security and yield generation.

• Custodian Partner: BitGo Trust Company, Inc. appointed in June 2025.
• Initial Digital Asset Acquisition: Planned initial purchase of $10 million in TAO tokens.
• Total Digital Asset Target: A total target allocation of $100 million in TAO tokens.
• Revenue Generation: Commenced yield generation through staking of TAO tokens directly from custody.

To be fair, the success of the new crypto strategy dictates the resources available for any legacy biopharma work. The Q3 2025 operating margin was 20.7%, up from 20.3% in 3Q24, which shows operational leverage in the current structure. Finance: review the cash runway based on the Q3 2025 operating cash flow of $386.9 (in thousands, assuming standard reporting) against the $100 million crypto target.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Cost Structure

The Cost Structure for Synaptogenix, Inc. (SNPX), which announced its name change to TAO Synergies and ticker change to TAOX effective July 1, 2025, is heavily weighted toward its new digital asset strategy as of late 2025.

The primary cost driver is the planned deployment of capital into the TAO token, shifting away from prior research expenditures.

Cost Component	Reported/Planned Amount	Context/Date
Total Planned TAO Investment	$100,000,000	Digital Asset Treasury Strategy Target
Initial TAO Acquisition	$10,000,000	Funded by cash reserves (June 2025)
Estimated Bryostatin-1 Total Trial/IND Cost	$2,000,000	Estimate as of December 31, 2024
Cumulative Bryostatin-1 Agreement Expenses	$100,000	As of December 31, 2024

Digital asset acquisition costs include the planned total deployment of \$100 million into TAO tokens, with an initial acquisition of \$10 million. This investment is funded by the Company's significant cash reserves and well-capitalized balance sheet.

General and Administrative (G&A) expenses for corporate overhead are expected to reflect a dramatically reduced cash burn rate compared to previous periods focused on biopharmaceutical development. Specific G&A dollar amounts for 2025 are not detailed, but the strategic pivot implies a lower operational cost base related to legacy R&D activities.

Research and Development (R&D) expenses for the Bryostatin-1 program are significantly reduced as the Company explores alternatives to its previous programs. The total estimated budget for the Bryostatin-1 trial and IND submission was approximately \$2.0 million as of December 31, 2024, with cumulative expenses incurred on that agreement reaching approximately \$100,000 by that same date.

Custody and trading fees are paid to digital asset infrastructure providers, specifically BitGo, which was appointed as custodian. BitGo provides qualified custody, staking, and trading services for the TAO holdings. Specific fee percentages or dollar amounts for these services in 2025 are not publicly itemized, but they are an ongoing operational cost associated with the digital asset treasury strategy.

Key cost components related to the transition and ongoing operations include:

• Digital asset acquisition outlay targeting $100,000,000 in TAO.
• Initial digital asset purchase of $10,000,000.
• Anticipated fees for custody and staking services provided by BitGo.
• Expected dramatic decline in cash burn rate related to legacy R&D.
• Historical estimated R&D cost for Bryostatin-1 trial at $2.0 million.

Synaptogenix, Inc. (SNPX) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Synaptogenix, Inc.'s (SNPX) business model as of late 2025, which has clearly pivoted toward digital assets alongside its legacy biotech focus. Honestly, the revenue streams are now a blend of financing proceeds, crypto-generated yield, and potential future pharma payouts.

The most concrete, recent cash inflow came from equity financing. On June 9, 2025, Synaptogenix, Inc. executed a Securities Purchase Agreement to raise $5.5 million in gross proceeds. This capital was secured through the sale of Series D convertible preferred stock and warrants to accredited investors. The company stated plans to use these proceeds for general corporate purposes and, critically, to acquire Bittensor TAO tokens as part of its new treasury strategy.

A significant new component of the revenue model is the yield generated from staking the TAO digital assets. Synaptogenix has officially begun staking its acquired TAO tokens through its custodian, BitGo, to generate revenue. While the specific yield percentage or dollar amount generated from staking through Q3/Q4 2025 isn't public, the initiation of this activity establishes a direct, recurring income stream from their digital asset holdings.

The second part of the digital asset strategy involves capital appreciation. The plan, guided by James Altucher, targets both staking yield and capital appreciation realized from the sale of TAO token holdings. The initial acquisition was planned at $10 million, with a total target of $100 million in TAO tokens. Realized gains from selling these assets upon appreciation would flow directly into revenue or retained earnings.

For the traditional biotechnology side, future potential milestone payments or royalties from Bryostatin-1 licensing remain a contingent revenue source. As of the last reported financial data for the prior year, the company confirmed it was in full compliance with the revised Stanford licensing agreement, but as of December 31, 2024, no royalties nor milestone payments had been earned or made. The estimated cost for the related IND trial was approximately $2.0 million.

Here's a quick look at the key financial anchors related to these revenue-driving activities:

Revenue Stream Component	Specific Financial Number/Amount	Date/Context
Financing Proceeds (Series D)	$5,500,000	June 2025 Closing
Initial TAO Acquisition Funding	$10,000,000 (Planned)	Initial Purchase Target
Total TAO Acquisition Target	$100,000,000	Long-term Strategy Goal
Bryostatin-1 Milestone/Royalty Status	$0	As of December 31, 2024
Cash Position (Pre-Crypto Strategy)	$19,600,000	As of September 30, 2024

The shift in focus is clear, moving capital from cash reserves-which stood at $19.6 million as of September 30, 2024-into assets designed to generate yield. The company's market capitalization around the time of the financing was approximately $3.35 million.

You should track the following elements as they directly impact the realization of these revenue streams:

• - Yield generated from staking the TAO digital assets.
• - Capital appreciation realized from the sale of TAO token holdings.
• - Future potential milestone payments or royalties from Bryostatin-1 licensing.
• - Proceeds from financing activities, like the $5.5 million preferred stock sale in June 2025.

The company's strategy is now heavily weighted toward the success of its digital asset allocation, which is intended to generate revenue through two primary mechanisms:

• - Direct yield from staking operations.
• - Profits from selling TAO tokens after capital appreciation.

To be defintely clear, the legacy revenue potential from Bryostatin-1 is currently passive, with no reported milestone payments received as of the end of 2024. Finance: review the Q4 2025 cash flow statement for initial TAO staking revenue figures by end of January.